2025年6月期通期の連結業績予想については、売上高が前期比5.5%増の233.50億円、営業利益が同5.4%増の46.20億円、経常利益が同5.3%増の46.00億円、親会社株主に帰属する当期純利益は同4.5%増の30.80億円を見込んでいる。On September 9th, Koa Shoji Holdings <9273> announced its consolidated financial results for the fiscal year ending June 2024. Revenue increased by 0.4% from the previous year to 22.134 billion yen, operating profit increased by 3.1% to 4.382 billion yen, ordinary profit increased by 6.7% to 4.368 billion yen, and net income attributable to parent company shareholders increased by 9.6% to 2.946 billion yen.
Sales revenue of the active pharmaceutical ingredient business was 15.455 billion yen (a decrease of 3.4% compared to the previous year), and segment profit was 2.769 billion yen (an increase of 1.5% compared to the previous year). Although there was an increase in the number of newly adopted items for the active pharmaceutical ingredients for "other metabolic pharmaceuticals" and "central nervous system drugs", there was a decrease in the sales quantity of customers due to inventory adjustments based on changes in inventory policies of customers for active pharmaceutical ingredients for "tumor drugs", adoption of competing active pharmaceutical ingredients for active pharmaceutical ingredients for "circulatory organs", and administrative measures for active pharmaceutical ingredients for "antibiotic preparations". However, trading of high-profit active pharmaceutical ingredients increased.
Sales revenue of the pharmaceutical manufacturing and sales business was 8.399 billion yen (up 6.5% from the previous year), and segment profit was 1.699 billion yen (up 10.8% from the previous year). The increase in sales quantity of the main injection product due to increased production and the favorable sales of existing products due to substitute demand from other companies in the same industry contributed to the increase.
For the fiscal year ending June 2025, the consolidated financial forecast is revenue of 23.35 billion yen (an increase of 5.5% compared to the previous year), operating profit of 4.62 billion yen (an increase of 5.4% compared to the previous year), ordinary profit of 4.6 billion yen (an increase of 5.3% compared to the previous year), and net income attributable to parent company shareholders of 3.08 billion yen (an increase of 4.5% compared to the previous year).
